Who are the top shareholders of the Samsrita Labs?

The top shareholders of Samsrita Labs are K Krishnam Raju with 19.58%, followed by M Neela Reddy at 4.67%, and individual investors collectively holding 44.75%. There are no mutual funds or foreign institutional investors involved.

The top shareholders of Samsrita Labs include K Krishnam Raju, who holds the highest promoter share at 19.58%. Following him, the highest public shareholder is M Neela Reddy, with a holding of 4.67%. Additionally, individual investors collectively hold 44.75% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

Has Samsrita Labs declared dividend?

No Dividend History Available

Who are the peers of the Samsrita Labs?

Samsrita Labs' peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Shree Pacetronix, Adeshwar Meditex, Family Care, and Chennai Meena. Poly Medicure has the highest 1-year return at 24.45%, while Samsrita Labs has a return of 20.20%.

Peers: The peers of Samsrita Labs are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Shree Pacetronix, Adeshwar Meditex, Family Care, and Chennai Meena.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and Shree Pacetronix, and the rest. Average management risk is noted at Family Care, while Below Average management risk is seen at Adeshwar Meditex. Growth is Excellent at Family Care, Below Average at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Shree Pacetronix, and the rest, and Average at Poly Medicure and Indegene. Capital Structure is Excellent at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and the rest, Good at Shree Pacetronix, and Below Average at Adeshwar Meditex.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.45%, while the peer with the lowest is Shree Pacetronix at -60.83%. Samsrita Labs has a 1-year return of 20.20%, which is lower than Poly Medicure's but higher than Shree Pacetronix's. Additionally, the six-month return is negative for Syngene Intl., Poly Medicure, Vijaya Diagnost., Shree Pacetronix, Adeshwar Meditex, Family Care, Chennai Meena, and Samsrita Labs.

Is Samsrita Labs overvalued or undervalued?

As of April 25, 2023, Samsrita Labs is rated as "risky" and overvalued with a negative PE ratio of -31.10 and an EV to EBIT ratio of -33.30, indicating significant financial struggles compared to peers like MMTC and Optiemus Infra, despite a recent 34.45% return.

As of 25 April 2023, Samsrita Labs has moved from a grade of "does not qualify" to "risky." The company is currently overvalued, as indicated by its negative PE ratio of -31.10 and an EV to EBIT ratio of -33.30. Additionally, the ROCE stands at -3.04%, which further highlights the company's financial struggles.<BR><BR>In comparison to peers, MMTC has a PE ratio of 119.39 and an EV to EBITDA of -70.04, while Optiemus Infra is considered fair with a PE ratio of 82.35 and an EV to EBITDA of 48.56. The stark contrast in these ratios suggests that Samsrita Labs is not only underperforming relative to its peers but also carries significant risk. Despite a recent 34.45% return over the past year, the overall valuation metrics indicate that the stock remains overvalued in the current market context.

What is the technical trend for Samsrita Labs?

As of May 12, 2025, Samsrita Labs shows a mildly bullish trend supported by positive MACD and KST indicators, despite some short-term weakness indicated by the RSI and daily moving averages.

As of 12 May 2025, the technical trend for Samsrita Labs has changed from sideways to mildly bullish. The weekly MACD is bullish, supporting the positive trend, while the monthly MACD is mildly bullish, indicating a gradual strengthening. The weekly KST is mildly bullish and the monthly KST is bullish, further reinforcing the upward momentum. However, the weekly RSI is bearish, suggesting some short-term weakness. The daily moving averages are mildly bearish, which contrasts with the overall bullish sentiment. Bollinger Bands are mildly bullish on both weekly and monthly time frames, indicating potential for price expansion. Overall, the current stance is mildly bullish, driven primarily by the MACD and KST indicators, despite some mixed signals from the RSI and moving averages.

When is the next results date for Samsrita Labs?

The next results date for Samsrita Labs is July 18, 2025.

The next results date for Samsrita Labs is scheduled for July 18, 2025.

Who are in the management team of Samsrita Labs?

As of March 2022, the management team of Samsrita Labs includes K Krishnam Raju (Chairman & Wholetime Director), K.N.V Narendra Kumar (Whole Time Director & CFO), and several independent directors: B Suryaprakash Rao, Aakanksha, Ramamohan Reddy Yarragudi, and A.S.S.V.Srinivas, along with Deepa Dudani as Company Secretary & Compliance Officer.

As of March 2022, the management team of Samsrita Labs includes the following individuals:<BR><BR>1. K Krishnam Raju - Chairman & Wholetime Director<BR>2. B Suryaprakash Rao - Independent Director<BR>3. K.N.V Narendra Kumar - Whole Time Director & CFO<BR>4. Aakanksha - Independent Director<BR>5. Ramamohan Reddy Yarragudi - Independent Director<BR>6. A.S.S.V.Srinivas - Independent Director<BR>7. Deepa Dudani - Company Secretary & Compliance Officer<BR><BR>Each member plays a distinct role in the governance and management of the company.

What does Samsrita Labs do?

Samsrita Labs Ltd is a micro-cap healthcare services company, formerly known as Dr Habeebullah Life Sciences Limited, with a market cap of INR 27 Cr and reported a net profit of -1 Cr for March 2025. The company has a debt-equity ratio of 0.18 and a return on equity of -2.12%.

Overview: <BR>Samsrita Labs Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Samsrita Labs Limited was incorporated on January 25, 1996, and was formerly known as Dr Habeebullah Life Sciences Limited until the name change on October 13, 2022. The latest quarterly results reported are for March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 27 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.18 <BR>Return on Equity: -2.12% <BR>Price to Book: 2.17<BR><BR>Contact Details: <BR>Address: Sy No 36 Chintalmet X Roads, Upperpally Attapur Rajendra Ng Hyderabad Telangana : 500048 <BR>Phone: 91-90300 57370 <BR>Email: pcproductsindia@gmail.com <BR>Website: https://drhlsl.com

How big is Samsrita Labs?

As of 24th July, Samsrita Labs Ltd has a market capitalization of 31.00 Cr, categorizing it as a Micro Cap company, with reported Net Sales of 0.00 Cr and a Net Profit loss of 0.26 Cr over the latest four quarters. Shareholder's Funds are valued at 12.26 Cr, and Total Assets amount to 15.55 Cr as of March 2024.

As of 24th July, Samsrita Labs Ltd has a market capitalization of 31.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>In the latest four quarters, Samsrita Labs reported Net Sales of 0.00 Cr. The Net Profit for the same period showed a loss of 0.26 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024. Shareholder's Funds are valued at 12.26 Cr, while Total Assets amount to 15.55 Cr.

How has been the historical performance of Samsrita Labs?

Samsrita Labs has experienced a declining trend in net sales, dropping from 2.01 Cr in March 2019 to 0.01 Cr in March 2021, alongside increasing losses, with an operating profit of -0.79 Cr in March 2021. The company's total liabilities and assets also decreased significantly during this period, indicating ongoing financial challenges.

Answer:<BR>The historical performance of Samsrita Labs shows a declining trend in net sales and increasing losses over the years.<BR><BR>Breakdown:<BR>Samsrita Labs reported net sales of 0.01 Cr in March 2021, a significant drop from 1.43 Cr in March 2020 and 2.01 Cr in March 2019. The total operating income followed a similar trend, decreasing from 1.43 Cr in March 2020 to 0.01 Cr in March 2021. The company faced substantial losses, with an operating profit (PBDIT) of -0.79 Cr in March 2021, improving slightly from -2.03 Cr in March 2020 but still reflecting ongoing operational challenges. Profit before tax was recorded at -0.80 Cr in March 2021, compared to -2.05 Cr in the previous year, while profit after tax also showed a loss of -0.78 Cr, down from -1.98 Cr in March 2020. The company's total liabilities decreased from 27.75 Cr in March 2020 to 16.58 Cr in March 2021, with total assets also declining from 27.75 Cr to 16.58 Cr in the same period. Cash flow from operating activities remained stagnant, with no inflow or outflow reported in the last two years. Overall, the financial data indicates a challenging period for Samsrita Labs, characterized by declining revenues and persistent losses.

Which are the latest news on Samsrita Labs?

Why is Samsrita Labs falling/rising?

As of 04-Dec, Samsrita Labs Ltd's stock price is rising to 21.57, up 2.71%, driven by strong relative performance and increased investor participation. Despite a year-to-date decline of 6.99%, the stock's current price exceeds several moving averages, indicating positive momentum.

As of 04-Dec, Samsrita Labs Ltd's stock price is rising, currently at 21.57, reflecting an increase of 0.57 or 2.71%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 2.69% today, indicating strong relative performance. Additionally, there has been a notable increase in investor participation, with a delivery volume of 719 on December 3rd, which is up by 63.26% compared to the 5-day average. This suggests growing interest and confidence among investors.<BR><BR>Moreover, the stock's current price is higher than its 5-day, 50-day, 100-day, and 200-day moving averages, although it remains lower than the 20-day moving average. This positioning relative to moving averages can often signal positive momentum. Overall, these factors contribute to the stock's rising price, despite its year-to-date performance showing a decline of 6.99% compared to the Sensex's gain of 9.12%.